This recommendation is based on the data safety monitoring board’s (DSMB) review of the blinded data from the first two-thirds of the 830 patients to be enrolled in two ongoing Phase III pivotal studies in Europe.
Robert Winslow, chairman, president and CEO of Sangart, said: “We are pleased to have a second positive DSMB recommendation as we continue to advance these important Phase III studies.”